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Abstract. Background: Intrinsic or acquired resistance to
chemotherapy is a major clinical problem leading to the fatality
of patients with advanced and metastatic breast cancer. The
overexpression of anti-apoptotic genes is believed to play a role
in the resistance to chemotherapy. In the present study, we
tested the sensitivity of MCF-7 breast cancer cells
overexpressing anti-apoptotic genes TRAF-1, c-FLIP, Bcl-xL,
cIAP-2 or Mn-SOD to paclitaxel and docetaxel. Materials and
Methods: MTT and trypan blue dye exclusion assays were
performed to examine the sensitivity of different cell lines to
docetaxel and paclitaxel. Cell cycle analysis and
carboxyfluorescein FLICA assay were employed to determine
whether defects in the cell cycle arrest or apoptotic pathway are
responsible for the resistance of cells overexpressing Bcl-xL or
c-FLIP. Caspase 8 and 9 activities were measured in cells
overexpressing Bcl-xL or c-FLIP exposed to docetaxel and
paclitaxel using fluorescent substrate cleavage assay. Results:
MCF-7 cells overexpressing Bcl-xL but not TRAF-1, cIAP-2 or
Mn-SOD were less sensitive to both paclitaxel and docetaxel
compared to vector-transfected control cells. Resistance of 
Bcl-xL-overexpressing cells to taxanes correlated with the
failure to activate caspase 9. 2-Methoxyantimycin A3, a
chemical inhibitor of Bcl-xL, sensitized Bcl-xL-overexpressing
cells to paclitaxel and docetaxel, which suggests the drugs that
inhibit Bcl-xL activity can be used as sensitizers to taxanes.
MCF-7 cells overexpressing c-FLIP were less sensitive to
paclitaxel but not to docetaxel. Paclitaxel failed to induce
caspase 8 in c-FLIP-overexpressing cells. Conclusion: Because
c-FLIP inhibits the extrinsic pathway of cell death whereas 
Bcl-xL inhibits the intrinsic pathway of cell death, these results
suggest that overexpression of anti-apoptotic genes that inhibit
either the extrinsic or intrinsic cell death pathways can reduce
sensitivity of cancer cells to paclitaxel, whereas anti-apoptotic
genes that inhibit only the intrinsic pathway reduce sensitivity
to docetaxel.
Adjuvant chemotherapy is the most crucial treatment in
reducing mortality in patients with advanced and metastatic
breast cancer (1, 2). Taxanes, docetaxel (taxotere) and
paclitaxel (taxol), are the common chemotherapeutic agents
used in breast cancer (2-4). Docetaxel and paclitaxel display
few overlapping as well as distinct properties. Both are
microtubule-stabilizing agents but induce a different set of
genes. They exert cytotoxicity by inducing mitotic arrest
followed by the activation of the mitochondrial (intrinsic)
and/or death receptor-dependent (extrinsic) pathways of cell
death (5-7).
Intrinsic or acquired resistance to chemotherapy is a major
clinical problem. Several factors including overexpression of
multidrug resistance and anti-apoptotic genes are believed to
play a role in resistance to chemotherapy. The expression of
a number of anti-apoptotic genes including cIAP-1, cIAP-2,
TRAF-1, TRAF-2, Bcl-2, Bfl-1/A1, Bcl-xL, c-FLIP and
manganese superoxide dismutase (Mn-SOD) is regulated by
the transcription factor NF-Î B (8-11). NF-Î B is an
extracellular signal activated transcription factor, which
usually resides in the cytoplasm of resting cells due its
2367
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association with the inhibitor of kappaB (IÎ B) proteins (8,
11). Upon exposure of cells to cytokines and growth factors
such as interleukin 1 (IL-1), tumor necrosis factor (TNF) or
epidermal growth factor, a series of signaling events trigger
phosphorylation and degradation of IÎ Bs. NF-Î B, liberated
from IÎ B, translocates to the nucleus, binds specific response
elements in the promoter region of target genes and regulates
gene expression.
Constitutive activation of NF-Î B is observed in a number
of cancers including breast cancer (10, 12). The constitutively
active NF-Î B in these cancers may contribute to
chemotherapeutic resistance by up-regulating the expression
of anti-apoptotic genes (9). We and others have shown that
inhibition of NF-Î B through either overexpression of IÎ Bs
or prior exposure to chemical NF-Î B inhibitors leads to
increased sensitivity of cancer cells to chemotherapeutic
drugs such as paclitaxel, docetaxel and CPT-11 (13-15).
In the present study, we sought to identify NF-Î B-
regulated anti-apoptotic genes involved in resistance to
taxanes. MCF-7 breast cancer cells are ideal for this study
because NF-Î B is not constitutively active in these cells and
inducible NF-Î B is less active due to interaction with
estrogen receptor (10, 16). Thus, it is possible to generate
derivatives of this cell line overexpressing individual NF-Î B-
regulated anti-apoptotic genes and evaluate the contribution
of individual genes in resistance to specific chemotherapeutic
drugs. The sensitivities of MCF-7 cells with vector alone or
overexpressing cIAP-2, TRAF-1, Mn-SOD, Bcl-xL or c-FLIP
to docetaxel and paclitaxel were compared. We observed
reduced sensitivity of cells overexpressing Bcl-xL to both
docetaxel and paclitaxel. Cells overexpressing c-FLIP showed
partial resistance to paclitaxel but not to docetaxel. The cells
overexpressing cIAP-2, TRAF-1 and Mn-SOD were as
sensitive as control cells to both drugs. 2-Methoxyantimycin
A3, a chemical inhibitor of Bcl-xL (17), increased the
sensitivity of Bcl-xL-overexpressing cells to docetaxel and
paclitaxel. Based on a recent report showing an important
role for Bcl-xL in survival and growth of breast cancer cells
at sites of metastasis (18), and our results highlighting the
importance of this gene in reducing the sensitivity of cancer
cells to commonly used chemotherapeutic drugs, we propose
that inhibitors of Bcl-xL function are necessary to reduce
metastasis as well as to increase the sensitivity of metastatic
cancer cells to chemotherapy.
Materials and Methods
Cell culture. MCF-7 breast cancer cells stably overexpressing
cIAP-2 and TRAF-1 were generated by transfecting pTRE2hyg
cIAP-2 and TRAF-1 cDNA constructs into MCF-7 cells, followed
by selection with 150 Ìg/ml hygromycin B. MCF-7 stably
overexpressing Mn-SOD cells were generated by transfecting
pcDNA3-Mn-SOD cDNA construct into MCF-7 cells, followed by
selection with 600 Ìg/ml G418. Empty vector pTRE-2hyg
(Clontech, Palo Alto, CA, USA) or pcDNA3 (Invitrogen,
Carlsbad, CA, USA) was transfected into MCF-7 cells to generate
control cells. MCF-7 cells overexpressing Bcl-xL and c-FLIP,
along with corresponding control cells of similar passage number,
were a generous gift of Dr. Marcus E. Peter (University of
Chicago, Chicago, IL, USA) (19, 20) and were originally
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generated in Drs. Vishva Dixit’s (Genentech, San Francisco, CA,
USA) and Xiaolu Yang’s (University of Pennsylvania)
laboratories. Note that these cells originated from different
laboraties and there are some differences in the growth media
and consequently behavior of control cells. Cells overexpressing
cIAP-2, TRAF-1 and Mn-SOD were maintained in Eagle
Minimum Essential Medium (EMEM) supplemented with 10%
fetal bovine serum (FBS). Bcl-xL cells were maintained in RPMI
1640 media supplemented with 10% FBS. c-FLIP cells were
maintained in Dulbecco’s Modified Eagle’s Medium (DMEM)
supplemented with 10% FBS.
MTT assay. Cells were plated at 2000 cells per well in 96-well tissue
culture plates. Different concentrations of docetaxel or paclitaxel were
added one day after culturing and replaced after three days. After six
days, the number of viable cells was determined using the celltiter non-
radioactive cell proliferation kit (Promega, Madison, WI, USA),
according to the instruction of the manufacturer. In each experiment,
cells in eight wells were treated with the same drug. Each data point is
the average of results obtained from three independent experiments.
Cell cycle analysis. Cells were grown in culture for 48 h before
treatment with vehicle or different drugs. The cells were trypsinized
and collected in media, and washed twice with PBS and
resuspended in 125 Ìl of 2 Ìg/ml RNase and 300 Ìl of propidium
iodide containing buffer (50 Ìg/ml propidium iodide, 1 mg/ml
sodium citrate, 0.03% NP40). The cells were analyzed on a
FACScan flow cytometer (Becton Dickon, Franklin Lakes, NJ,
USA). The cell cycle distribution was determined using the ModFit
computer software. All cell cycle assays were performed three
times and representative data is presented in the text.
Cell death assay. The carboxyfluorescein FLICA apoptosis detection
kit (Immunohistochemistry Technologies, LLC, Bloomington, MN,
USA) was used to measure typical apoptosis, atypical apoptosis and
necrosis (21, 22). Briefly, 2x105 cells grown overnight on a 60-mm
plate were exposed with the indicated drugs for 3 days. Both
floating and attached cells were collected by trypsinization and
incubated with carboxyfluorescein-labelled pan-caspase inhibitor
FAM-VAD-FMK for 2 h at 37ÆC. The labelled cells were rinsed
twice in washing buffer and resuspended in 400 Ìl of the washing
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buffer containing 0.4 Ìg of propidium iodide. Apoptotic cells were
identified by FACScan analysis as described previously (22). All
apoptosis assays were performed three times and representative
data is presented in the text.
Western blot analysis. Cell lysates prepared in radioimmunoassay
buffer were subjected to Western blot, as described previously (13).
Caspase 8 and 9 activities assay. Caspase 8 or 9 activities were
measured using fluorogenic caspase 8 or 9 substrate, respectively
(Ac-IEPD-AMC or Ac-LEHD-AMC, Alexis, San Diego, CA,
USA). Briefly, 1x106 cells, grown overnight in 100-mm dishes, were
treated with the indicated drugs for 48 h. Both floating and
attached cells were collected by trypsinization and lysed in 150 Ìl of
lysis buffer (50 mM PIPES, pH 7.0, 50 mM KCl, 5 mM EGTA, 
2 mM MgCl2 and 1 mM DTT). After incubation on ice for 30
minutes, the lysate was collected by centrifugation. Fifty Ìl of cell
lysate was incubated with 50 Ìl of 2 x reaction buffer (20 mM
HEPES, pH7.5, 20% sucrose, 0.2% CHAPS, 0.2 mg/ml BSA and
20 mM DTT) and 5 Ìl of 1 mM caspase 8 or 9 substrate for 1 h at
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37ÆC. Caspase 8 or 9 activities were measured at an excitation
wavelength of 380 nm and emission wavelength of 460 nm. Caspase
8 or 9 activities were normalized to protein concentration and basal
activity in untreated cells was set as one unit. All assays were
performed three times. 
RNAse protection assay. RNase protection assay with human APO2
probe (BD Biosciences) was performed as described previously
(13). RNA from untreated MCF-7 and MDA-MB-231 cells for 4 h
was used in the RNase protection assay.
Statistical analysis. Data were analyzed using GraphPad software
(Graphpad.com). Analysis of variance was employed to determine
p values between mean measurements. A p value <0.05 was
deemed significant. Error bars on all histograms in this text
represent the standard deviation between measurements from
duplicate experiments.
Results
Overexpression of Bcl-xL leads to reduced sensitivity of MCF-7
breast cancer cells to docetaxel or paclitaxel. We sought to
identify NF-Î B regulated anti-apoptotic genes involved in
resistance to taxanes using MCF-7 breast cancer cells
overexpressing TRAF-1, c-FLIP, c-IAP2, Mn-SOD or Bcl-xL
(8, 9). The expression of TRAF-1, Mn-SOD or cIAP-2 was
confirmed by Western blotting or reverse transcriptase-
polymerase chain reaction (RT-PCR) (Figure 1A).
Overexpression of these genes had no effect on basal NF-Î B
DNA binding activity (data not shown). MTT assay was
performed to examine the sensitivity of different cell lines to
docetaxel and paclitaxel. As shown in Figure 1B, only cells
overexpressing Bcl-xL showed reduced sensitivity to docetaxel
and paclitaxel compared to vector control cells. The cells
overexpressing c-FLIP were modestly resistant to paclitaxel
but not to docetaxel. Results from the trypan blue dye
exclusion assay were consistent with those from MTT assay
(data not shown). In addition, docetaxel was effective at a
lower concentration than paclitaxel, which is consistent with
previous studies (23, 24).
To determine whether the differential sensitivity of Bcl-xL-
and c-FLIP-overexpressing cells to taxanes compared to vector
control cells is due to changes in proliferation rate, the rate of
cell proliferation was measured by MTT assay (Figure 1C). The
cells overexpressing Bcl-xL grew slower than control cells, while
the cells overexpressing c-FLIP showed slightly faster growth
than control cells, suggesting that there is no correlation
between the cell proliferation rate and drug sensitivity.
Delayed G2/M arrest in cells overexpressing Bcl-xL but not
c-FLIP upon taxane treatment. Taxanes bind and stabilize
microtubules leading to mitotic arrest followed by
apoptosis (6). To assess whether reduced sensitivity of
Bcl-xL cells to taxanes is due to defects in cell cycle arrest,
we performed cell cycle analysis of untreated and drug-
treated cells. As summarized in Figure 2, G2/M arrest was
delayed in Bcl-xL-overexpressing cells compared to
control cells. For example, after 8-h drug treatment, only
control cells were arrested at G2/M. However, at 24 h
post-treatment, both control and Bcl-xL-overexpressing
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Figure 1. Sensitivity of MCF-7 cell derivatives to docetaxel and paclitaxel. A) Expression levels of Mn-SOD, TRAF-1 and cIAP-2 in overexpressing cells.
Mn-SOD and TRAF-1 expression was determined by Western blotting, whereas cIAP-2 expression was measured by RT-PCR. B) Sensitivity of cells to
various concentrations of docetaxel and paclitaxel was measured by MTT assay as described in Materials and Methods. *p<0.001 C) Proliferation rate
of control, Bcl-xL- and c-FLIP-overexpressing cells. *p<0.001 **p=0.08
1C
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Figure 2. The effect of docetaxel and paclitaxel on cell cycle distribution of control and Bcl-xL-overexpressing cells. Cells were treated with drugs for the
indicated times and cell cycle distribution was measured by flow cytometry. Representative data from three experiments is shown.
2B
cells accumulated at G2/M-phase at a similar level.
Interestingly, the proportion of untreated Bcl-xL cells in
S-phase was always higher compared to untreated control
cells, which suggests that Bcl-xL-overexpressing cells take
a longer time to complete S-phase or that Bcl-xL delays
the entry of cells from S-phase to G2/M. The delay in taxane-
induced G2/M arrest of Bcl-xL-overexpressing cells could be
a consequence of prolonged S-phase in these cells. Docetaxel-
induced G2/M arrest was not affected in cells overexpressing
cIAP-2, TRAF-1, Mn-SOD or c-FLIP (data not shown).
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Figure 3. The effect of docetaxel and paclitaxel on apoptosis of control, Bcl-xL- and c-FLIP-overexpressing cells. A) Apoptosis was measured using
carboxyfluorescein FLICA. Apoptosis was measured three days after treatment. X-axis, propidium iodide staining; Y-axis, active caspase staining; lower
left, live cells; upper left, apoptotic cells, lower right, necrotic cells and upper right, atypical apoptotic cells. Representative data from three experiments
is shown. B) Caspase 8 and 9 activities in cells treated with docetaxel or paclitaxel for 48 h. Caspase 8 or 9 activities were measured using the substrate
Ac-IEPD-AMC or Ac-LEHD-AMC, respectively, as described in Materials and Methods.
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Defects in taxane-induced apoptosis in cells overexpressing 
Bcl-xL and c-FLIP. To further determine whether defects in
the apoptotic pathway are responsible for the resistance of
cells overexpressing Bcl-xL and c-FLIP to taxanes, apoptosis
of drug-treated cells was measured using the carboxy-
fluorescein FLICA assay. This assay simultaneously
measures the level of active caspases and the loss of plasma
membrane integrity, thus allowing quantitation of live,
apoptotic, atypical apoptotic (with loss of plasma membrane
integrity) and necrotic cells (21, 22). Since the FLICA assay
is less sensitive than the MTT assay employed in Figure 1B,
higher concentrations (≥0.5 ÌM) of paclitaxel were used to
detect significant apoptosis. Cells overexpressing Bcl-xL or
c-FLIP showed significantly decreased typical and atypical
apoptosis and increased cell survival when treated with
paclitaxel at different concentrations, while cells
overexpressing Bcl-xL but not c-FLIP displayed increased
cell survival when treated with docetaxel (Figure 3A, data
not shown). Thus, the resistance to paclitaxel and/or
docetaxel appears to be due to an impaired apoptotic
pathway in cells overexpressing c-FLIP or Bcl-xL.
To determine whether taxanes are less efficient in
inducing caspase activity in cells overexpressing Bcl-xL or
c-FLIP, we measured the activities of caspase 8 and 9,
which are major caspases in the extrinsic and/or intrinsic
apoptosis pathways using a fluorescent substrate cleavage
assay (Figure 3B). We did not examine caspase 3 activity
because MCF-7 cells lack the caspase 3 gene (25).
Paclitaxel was more efficient in inducing caspase 8, whereas
docetaxel was more efficient in inducing caspase 9 in
control cells (Figure 3B). Note that, as with cell death
assays, a higher concentration of paclitaxel compared to
docetaxel was required to observe caspase activation.
Despite the lower concentration, docetaxel was still more
efficient than paclitaxel in inducing caspase 9. Both
paclitaxel and docetaxel failed to induce caspase 9 in 
Bcl-xL-overexpressing cells. Paclitaxel-induced caspase 8
activity was lower in Bcl-xL-overexpressing cells compared
to control cells. While c-FLIP overexpression had no effect
on docetaxel-induced caspase 9 activation, c-FLIP reduced
paclitaxel-induced caspase 8 and caspase 9 activation. Thus,
Bcl-xL and c-FLIP protect cancer cells against taxanes by
reducing caspase activation.
2-Methoxyantimycin A3, a chemical inhibitor of Bcl-xL,
sensitizes cancer cells with high levels of Bcl-xL to paclitaxel
and docetaxel. To confirm that Bcl-xL is responsible for
taxane resistance, we treated cells with taxanes along with
2-methoxyantimycin A3, which selectively inhibits Bcl-xL
function by binding to its hydrophobic groove (17). As
shown in Figure 4 A, 2-methoxyantimycin A3 alone had no
effect on both control and Bcl-xL-overexpressing cells.
Paclitaxel and docetaxel in combination with 
2-methoxyantimycin A3 caused significant cytotoxicity to
Bcl-xL-overexpressing cells. Since MCF-7 cells lack caspase
3 expression, we sought to further investigate if 
2-methoxyantimycin A3 sensitizes MDA-MB-231 cells,
which contains caspase 3 and constitutively active NF-Î B
activity, to taxanes . The RNase protection assay showed
that MDA-MB-231 cells express a higher Bcl-xL mRNA
level compared to MCF-7 cells (Figure 4B). MDA-MB-231
cells showed increased typical and atypical apoptosis when
treated with a combination of 2-methoxyantimycin A3 and
paclitaxel or docetaxel (Figure 4C). These results suggest
that inhibitors of Bcl-xL can be used to increase the
sensitivity of cancer cells to taxanes.




Both paclitaxel and docetaxel are considered to be
microtubule-targeted tubulin-polymerizing agents (MTPAs)
(6). Previous studies suggest that MTPAs induce G2/M
arrest and subsequent apoptosis through the mitochondrial
pathway (6, 7). Bcl-xL but not c-FLIP caused a delay in
docetaxel-induced G2/M arrest. The adaptor protein c-FLIP
serves as an anti-apoptotic gene in the death receptor
pathway (26). It competes with caspase 8 for binding to
FADD and inhibits caspase 8 activation, which is an essential
step in initiation of the extrinsic death pathway. Moos and
Fitzpatrick demonstrated that paclitaxel, but not docetaxel
stimulates TNF· production (5). Neutralizing antibodies
against TNF· reduced paclitaxel- but not docetaxel-induced
cell death, suggesting the TNF·-induced extrinsic apoptosis
is an integral part of paclitaxel-mediated cell death (5).
Consistent with this possibility, we observed elevated caspase
8 activation by paclitaxel compared to docetaxel, which was
inhibited by c-FLIP (Figure 3B). Thus, the resistance of 
c-FLIP-overexpressing cells to paclitaxel is due to inefficient
activation of the extrinsic cell death pathway. Activated
caspase 8 may be involved in feed-forward activation of the
intrinsic cell death pathway in paclitaxel-treated cells,
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Figure 4. 2-Methoxyantimycin A3, a chemical inhibitor of Bcl-xL, reverses resistance of cancer cells with high levels of Bcl-xL to taxanes. A) MCF-7 cells
overexpressing Bcl-xL were treated with indicated drugs for three days and cell death was measured by MTT assay *p<0.001. B) RNA from MCF-7 and
MDA-MB-231 cells for 4 h was subjected to RNase protection assay. C) MDA-231 cells were treated with a combination of 10 Ìg/ml 2-methoxyantimycin
A3 and paclitaxel or docetaxel for 48 h and apoptosis was measured as in Figure 3A.
4C
because paclitaxel failed to induce caspase 9 in both Bcl-xL-
and c-FLIP-overexpressing cells (Figure 3B). Because
docetaxel-induced cell death is dependent mostly on the
intrinsic cell death pathway, c-FLIP-overexpressing cells
were still sensitive to this drug. Although TRAF-1 is an
inhibitor of the extrinsic pathway of cell death (27), it was
unable to confer resistance to paclitaxel. TRAF-1 is mostly
involved in signaling by CD40 and its anti-apoptotic function
may be signal-dependent (28).
The failure of cIAP-2 and Mn-SOD, both of which
antagonize the intrinsic cell death pathway, to protect
against taxanes is rather surprising (29, 30). The anti-
apoptotic function of cIAP-2 in the intrinsic cell death
pathway is downstream of mitochondria (30). It inhibits
activation of caspase 9 in the apoptosome and inhibits the
activity of processed caspase 3. It is possible that once the
mitochondria are damaged, apoptosis is irreversible and the
anti-apoptotic proteins functioning downstream of
mitochondria are not potent enough to prevent apoptosis.
Mn-SOD scavenges reactive oxygen species and, thus,
reduces mitochondrial damage (31). Paclitaxel- and possibly
docetaxel-induced cell death in our assays less likely involve
oxidative stress because previous studies have shown that
paclitaxel up to one ÌM does not induce oxidative stress in
MCF-7 cells (32). This may explain the differences in our
results with that of Manna et al. (33), who showed enhanced
survival of MCF-7 cells overexpressing Mn-SOD treated
with 25 ÌM paclitaxel.
Cells selected for paclitaxel resistance in vitro have been
shown to overexpress Bcl-2 or Bcl-xL (6, 34). Bcl-xL-
mediated resistance to taxanes may involve defects in cell
cycle arrest, apoptosis or both. We observed a delay in
taxane-induced G2/M arrest of Bcl-xL cells compared to
control cells (Figure 2). The consequences of this delay on
ultimate cell death are not known. It is possible that Bcl-xL-
mediated delay in G2/M arrest may have an impact on drug
sensitivity in vivo depending on the rate of drug clearance.
Alternatively, Bcl-xL-mediated delay in G2/M arrest has no
consequence on cell death, but it blocks the release of
cytochrome c from the mitochondria and subsequent
activation of caspases (6). The apoptosis assay clearly
indicates reduced caspase activation in Bcl-xL-
overexpressing cells compared to control cells (Figure 3).
In addition to its role in drug resistance, Bcl-xL has been
identified recently as an enhancer of metastasis, but not
primary tumor growth (18). This is consistent with our
observation that cells overexpressing Bcl-xL are refractory
to treatment with paclitaxel and docetaxel, but display
slower growth compared to control vector cells.
Overexpression of Bcl-xL correlates with increased nodal
involvement and higher tumor grade in human breast cancer
patients (34). In metastatic human breast tumor cell lines,
overexpression of Bcl-xL can increase cell survival in the
vasculature and enhance the formation of distant metastases
(18). Our results suggest that chemotherapeutic drugs may
efficiently eliminate tumor cells that express a low level of
Bcl-xL at primary tumor sites as well as at sites of metastasis
and few tumor cells that overexpress Bcl-xL survive.
Regrowth of these Bcl-xL-overexpressing tumor cells leads
to recurrence of the tumor at metastatic sites and a poor
prognosis. A significant observation of this present study is
that inhibition of Bcl-xL expression by a specific inhibitor 
2-methoxyantimycin A3 dramatically sensitized the Bcl-xL-
overexpressing cells and cells with high levels of Bcl-xL to
paclitaxel and docetaxel, implying that a promising strategy
of Bcl-xL inhibitor or anti-sense molecule in combination
with paclitaxel or docetaxel may benefit patients with
chemotherapy-resistant metastatic breast cancers.
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